Skip to content

Pharmaceutical care in the basic health unit

Pharmaceutical care in primary care

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-9hcw2k
Enrollment
Unknown
Registered
2016-02-22
Start date
2014-06-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome

Interventions

Experimental group: 33 individuals of both sexes, diagnosed with metabolic syndrome according to the criteria defined by the National Cholesterol Education Program / Adult Treatment Panel III (NCEP /
Behavioural
Other

Sponsors

Universidade Estadual da Paraíba
Lead Sponsor
Universidade Estadual da Paraíba
Collaborator

Eligibility

Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: patients with metabolic syndrome; both genders; age above 18 years

Exclusion criteria

Exclusion criteria: pregnant women; people with cognitive difficulties

Design outcomes

Primary

MeasureTime frame
Improvement of the metabolic syndrome monitoring parameters (blood pressure, blood glucose, lipid and anthropometric profile). The effectiveness of pharmaceutical interventions was measured comparing yourself the measured values ??at the beginning and end of the blood pressure study (BP), fasting glucose, total cholesterol (TC), triglycerides (TG), cholesterol HDL (High density lipoprotein), cholesterol LDL (Low density lipoprotein), waist circumference (WC), body mass index (BMI). To check the biochemical profile, blood samples from each participant were obtained by venipuncture after 12 hours fasting in the collection room of the Maternity Hospital Municipal de Cuité, by a qualified professional. Analyses were performed on the same day, by enzymatic method, biochemical analyzer Bioplus 2000 and Kit's Labtest reagents in the clinical laboratory of the mentioned hospital. The determination of LDL-cholesterol to serum triglycerides less than 400 mg / dL was obtained by the Friedewald equation: LDL-c = TC - HDL-C - TG / 5. For blood pressure measurement was used digital electronic sphygmomanometer arm brand VISOMAT COMFORT III. Body weight was obtained in electronic anthropometric scale WISO W904i model (Crivitta Diagnostic, Brazil). Patients were told to be empty bladder, wearing light clothing and no shoes, with your arms at your sides. The measurement of waist circumference (WC) was performed with the patient standing, with arms extended along the body and feet together with inelastic and tape measure at the end of expiration, measured surrounding the abdominal region at the midpoint the distance between the iliac crest and the lower costal margin. The cutoff point was 102 cm for men and 88 cm for women. Body mass index (BMI) was calculated as the ratio of weight (kg) / height 2 (m). Made statistical analysis were considered significant P values ??less than 0.05.;Improvement in medication adherence The effectiveness of pharmaceutical interventions was measured by c

Secondary

MeasureTime frame
Improved quality of life Quality of life was assessed by applying the World Health Organization Quality of Life (WHOQOL-BREF). After statistical analysis were considered significant P values less than 0.05.;Decrease cardiovascular risk in 10 years. The calculation of the absolute risk of coronary events in 10 years used the Framingham Risk Score. Made statistical analysis were considered Significant P values less than 0.05.

Countries

Brazil

Contacts

Public ContactMaria da Batista de Azevedo

Universidade Estadual da Paraíba

gloria.farmacia@hotmail.com+55 (83) 3372-1933

Outcome results

None listed

Source: REBEC (via WHO ICTRP)